[{"id":"f851164b-12cc-4802-a431-f0b4ed742c5e","acronym":"VELA","url":"https://clinicaltrials.gov/study/NCT05252416","created_at":"2022-02-23T19:55:05.515Z","updated_at":"2024-07-02T16:35:07.979Z","phase":"Phase 1/2","brief_title":"(VELA) Study of BLU-222 in Advanced Solid Tumors","source_id_and_acronym":"NCT05252416 - VELA","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" HER-2 • CCNE1","pipe":" | ","alterations":" HER-2 negative • CCNE1 amplification","tags":["HER-2 • CCNE1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • CCNE1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Kisqali (ribociclib) • fulvestrant • cirtociclib (BLU-222)"],"overall_status":"Recruiting","enrollment":" Enrollment 366","initiation":"Initiation: 04/07/2022","start_date":" 04/07/2022","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-04-23"}]